Activation of σ(C-H) bonds in ferrocenylhydrazones derived from acetylferrocene

Cyclopalladation of a ferrocene acylphosphine and the reactivity of the C-H activated products

Acylphosphines are an attractive subclass of phosphine ligands with specific reactivity and ligating properties. This study describes the synthesis of a ferrocene-based acylphosphine, FcC(O)PPh₂ (1, Fc = ferrocenyl), the corresponding phosphine chalcogenides FcC(O)P(E)Ph₂ (E = O, S and Se), and palladium(ii) complexes resulting from the orthometallation of 1, viz. [Pd(μ-X)(1- H)]₂ (2-X, where X = Cl, Br and I), which in turn serve as a convenient entry point to a range of monopalladium complexes. Thus, the cleavage of 2-X with phosphines, 4-(dimethylamino)pyridine and in situ-generated 1,3-dimesitylimidazolin-2-ylidene (L) provided complexes [PdX(L)(1- H)] (3-5), which are typically obtained as single isomers by crystallisation but undergo spontaneous isomerisation in solution leading to equilibrium mixtures of cis and trans isomers. Upon treatment with sodium acetylacetonate (Na(acac)), 2-Cl was transformed into [Pd(acac)(1- H)] (6), which reacted with (diphenylphosphino)acetic acid under proton transfer to give [Pd(Ph₂PCH₂CO₂-κ²O,P)(1- H)] (7), while the reaction with allylating agents produced the π-allyl complex [Pd(η³-C₃H₅)(1- H)] (9). Compound [PdCl(PMe₃)(1- H)] was further used to prepare a series of diorganopalladium complexes [Pd(R)(PMe₃)(1- H)] (8; R = Me, 4-C₆H₄Me, 4-C₆H₄CF₃, CH[double bond, length as m-dash]CHC₆H₄Me-4 and C[triple bond, length as m-dash]CC₆H₄Me-4). All compounds were structurally characterised using spectroscopic methods and, in most cases, also by X-ray diffraction analysis. The structural data indicated the rigidity of the Pd(1- H)⁺ fragment and revealed variations in the Pd-donor distances dictated by an interplay between the trans influence and steric demands of the ligands surrounding Pd(ii). Moreover, some compounds were studied by DFT to rationalise their isomerisation equilibria and electrochemical properties, which were examined by cyclic voltammetry.

Novel multifunctional and multitarget homo- (Fe2) and heterobimetallic [(Fe,M) with M = Re or Mn] sulfonyl hydrazones

The synthesis and characterization of the novel ferrocenyl sulfonyl hydrazide [Fe(η5-C5H5){(η5-C5H4)-S(O)2-NH-NH2}] (2) is reported. Additional studies on its reactivity using acetone or the ferrocenyl-, cyrhetrenyl- or cymantrenyl-aldehydes have allowed us to isolate and characterize [Fe(η5-C5H5){(η5-C5H4)-S(O)2-NH-N[double bond, length as m-dash]CMe2}] (3), the bis(ferrocenyl) derivative [Fe(η5-C5H5){[(η5-C5H4)-S(O)2-NH-N[double bond, length as m-dash]CH-(η5-C5H4)]Fe(η5-C5H5)}] (4) and the heterodimetallic compounds [Fe(η5-C5H5){[(η5-C5H4)-S(O)2-NH-N[double bond, length as m-dash]CH-(η5-C5H4)]M(CO)3}] with M = Re (5a) or Mn (5b). The X-ray crystal structures of compounds 3, 5a and 5b are also reported. A comparative study of their electrochemical and spectroscopic properties is also described. Additional computational calculations based on the DFT methodology have allowed us to elucidate the effect produced by the replacement of the terminal -NH2 (in 2) by the -N[double bond, length as m-dash]CMe2 (in 3) and -N[double bond, length as m-dash]CHR (in 4, 5a and 5b) moieties on the electronic distribution and to explain the differences detected in their electrochemical properties and absorption spectra. In vitro cytotoxicity studies of compounds 2, 4, 5a and 5b on the HCT-116 (colon), MCF7 and MDA-MB231 (breast) cancer cell lines reveal that compound 2 has no significant activity (IC50 > 100 μM), while its derivatives 4, 5a and 5b proved to be active in the three cancer cell lines selected in this study. The growth inhibition potency of compounds 5a and 5b against the triple negative MDA-MB231 breast cancer cell line is similar (or slightly) greater than that of cisplatin. Moreover, compounds 2, 4, 5a and 5b are less toxic than cisplatin in the normal and non-tumoral BJ fibroblasts, and the heterodimetallic complexes 5a and 5b with selective index >2.1 show an outstanding selective toxicity towards the MDA-MB231 cancer cells.